Literature DB >> 18079740

JAK2 Mutations are present in all cases of polycythemia vera.

Y L Wang, K Vandris, A Jones, N C P Cross, P Christos, F Adriano, R T Silver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18079740     DOI： 10.1038/sj.leu.2405047

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  21 in total

Review 1.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

2.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

Review 3.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Authors:  Emil T Kuriakose; Stefani Gjoni; Y Lynn Wang; Ruth Baumann; Amy V Jones; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

5.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors:  Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

6.  Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Authors:  Jason D Merker; Carol D Jones; Stephen T Oh; Iris Schrijver; Jason Gotlib; James L Zehnder
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

7.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

8.  JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.

Authors:  Richard T Silver; Katherine Vandris; Y Lynn Wang; Fernando Adriano; Amy V Jones; Paul J Christos; Nicholas C P Cross
Journal:  Leuk Res       Date:  2010-07-22       Impact factor: 3.156

9.  JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.

Authors:  Friederike Pastore; Aishwarya Krishnan; Henrik M Hammarén; Olli Silvennoinen; Benedict Yan; Ross L Levine
Journal:  Blood Adv       Date:  2020-09-22

Review 10.  Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.

Authors:  Alfonso Quintás-Cardama; Srdan Verstovsek
Journal:  Clin Cancer Res       Date:  2013-02-13       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.